Join
Live feed
·
PRReleasevia Quantisnow
Ionis Pharmaceuticals Inc. logo

Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS

ByQuantisnow·Wall Street's wire, on your screen.
IONS· Ionis Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IONS (Ionis Pharmaceuticals Inc.) and more on Quantisnow.